Abciximab readministration.
Rev Cardiovasc Med
; 3(2): 67-70, 2002.
Article
en En
| MEDLINE
| ID: mdl-12447149
ABSTRACT
The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Trombocitopenia
/
Fragmentos Fab de Inmunoglobulinas
/
Inhibidores de Agregación Plaquetaria
/
Complejo GPIIb-IIIa de Glicoproteína Plaquetaria
/
Enfermedad Coronaria
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Rev Cardiovasc Med
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2002
Tipo del documento:
Article
País de afiliación:
Estados Unidos